Pramlintide

What it is

Pramlintide (Symlin) is a synthetic analog of human amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Native amylin is amyloidogenic (prone to forming aggregates), so pramlintide includes three amino acid substitutions (proline at positions 25, 28, and 29) that prevent aggregation while preserving biological activity. It was FDA-approved in 2005 for use in type 1 and insulin-treated type 2 diabetes.

Mechanism of action

Pramlintide acts at amylin receptors in the brain, particularly the area postrema, producing slowed gastric emptying, glucagon suppression, and increased satiety. The combination of effects reduces postprandial glucose excursions and improves overall glycemic control in patients on insulin therapy. The mechanism is complementary to insulin’s direct effects on glucose disposal.

Approved indications and clinical use

Pramlintide is approved as adjunctive therapy in patients with type 1 diabetes or insulin-treated type 2 diabetes who have failed to achieve glycemic targets despite optimal insulin therapy. It is administered subcutaneously immediately before meals. Use requires careful coordination with insulin dosing — pramlintide initiation typically requires reducing meal-time insulin doses by approximately 50% to avoid hypoglycemia.

Why this is out of scope at The Tide

Pramlintide is used specifically in insulin-treated diabetes, which is appropriately managed by endocrinology or experienced primary care physicians who oversee the patient’s complete insulin regimen. The interaction with insulin requires expertise in diabetes management that is outside the scope of our peptide-focused outpatient practice. Patients with type 1 diabetes or complex type 2 diabetes requiring insulin should receive coordinated diabetes care from endocrinology.

Where to learn more

Patients interested in pramlintide should discuss with their endocrinologist or diabetes care provider. The FDA prescribing information and the American Diabetes Association guidelines provide comprehensive clinical information.